Terns’s stock soars as analysts cheer leukemia data — and predict more gains 4 de dezembro de 2024 by in News The pharma company now has two positive proof-of-concept trials under its belt, including its weight-loss pill. Compartilhe isso:Clique para compartilhar no Twitter(abre em nova janela)Clique para compartilhar no Facebook(abre em nova janela) Relacionado 4 de dezembro de 2024